FDA approves Olumiant for certain adults hospitalized with COVID-19

The FDA has approved a new indication for Olumiant as a treatment for adults hospitalized with COVID-19 who require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
The Janus kinase inhibitor Olumiant (baricitinib; Eli Lilly & Co.) is the first immunomodulatory treatment to be approved by the FDA for COVID-19, according to the agency.
The FDA previously granted emergency use authorization (EUA) to baricitinib for use in combination with Veklury (remdesivir; Gilead Sciences) as a treatment for adults and pediatric patients

The FDA has approved a new indication for Olumiant as a treatment for adults hospitalized with COVID-19 who require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
The Janus kinase inhibitor Olumiant (baricitinib; Eli Lilly & Co.) is the first immunomodulatory treatment to be approved by the FDA for COVID-19, according to the agency.
The FDA previously granted emergency use authorization (EUA) to baricitinib for use in combination with Veklury (remdesivir; Gilead Sciences) as a treatment for adults and pediatric patients